With positive progress in ongoing clinical studies, Hoth Therapeutics aims to provide patients access to HT-001 outside of traditional clinical trials through the Expanded Access Program (EAP ...
Hoth Therapeutics (HOTH) announced its intention to submit an Expanded Access application for HT-001, its novel therapeutic candidate for the treatment of dermatological conditions associated with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback